You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Healthcare-associated infections

Letermovir for preventing cytomegalovirus disease after a stem cell transplant

  • Technology appraisal guidance
  • Reference number: TA591
  • Published:  31 July 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Draft guidance: 1
  4. Invitation to participate
  5. Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 152 KB)

    Published:
    31 July 2019

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 310 KB)

    Published:
    30 May 2019
  • Committee papers (PDF 970 KB)

    Published:
    30 May 2019
  • Public committee slides (PowerPoint 154 KB)

    Published:
    30 May 2019

Draft guidance: 1

  • Draft guidance: 1

  • Appraisal consultation document (PDF 357 KB)

    Published:
    04 July 2018
  • Public committee slides (PDF 1.06 MB)

    Published:
    04 July 2018
  • Committee papers (PDF 19.36 MB)

    Published:
    04 July 2018

Invitation to participate

  • Final scope (PDF 214 KB)

    Published:
    09 January 2018
  • NICE's response to comments on the draft scope and provisional matrix (PDF 331 KB)

    Published:
    09 January 2018
  • Equality impact assessment (Scoping) (PDF 176 KB)

    Published:
    09 January 2018
  • Final matrix (PDF 265 KB)

    Published:
    09 January 2018

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Draft matrix pre referral (PDF 300 KB)

    Published:
    21 July 2017
  • Draft scope pre referral (PDF 303 KB)

    Published:
    21 July 2017
Back to top